At Late-Night ASH Talk Juno Execs Look Beyond Stalled Rocket Trial

December 06, 2016 | Juno Therapeutics is still mulling next steps for its lead product, an experimental cancer immunotherapy now stuck in limbo because five of 68 adult leukemia patients in its current study have died from severe brain swelling caused by the treatment. Xconomy